COMPANY PROFILE

Airway Therapeutics

Explore full profile

Develops zelpultide alfa, a recombinant biologic for respiratory, inflammatory and infectious diseases.

Atlanta, United StatesFounded 2011Biotech & Life Sciences

Valuation $250–500M Last recorded · 2026

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Airway Therapeutics

Airway Therapeutics is a clinical-stage biopharmaceutical company developing biologic therapies for respiratory, inflammatory and infectious diseases. Its lead programme, zelpultide alfa, is a recombinant human surfactant protein D designed to modulate excessive inflammation, support pathogen recognition and clearance, and maintain pulmonary function. The programme is being evaluated in a Phase 2b/3 clinical trial for the prevention of bronchopulmonary dysplasia in very preterm infants, and is also being explored for conditions including pneumonia, acute respiratory distress syndrome, chronic obstructive pulmonary disease, influenza and pulmonary fibrosis. Airway Therapeutics operates an R&D-led model focused on clinical development, manufacturing readiness and potential future commercialisation across neonatal and adult respiratory care.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2011
Headquarters: Atlanta, United States
Employees: 16
Open positions: None listed
Dealroom signal: 82.4/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

9 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES COther financing	Jan 2020	$16M	$62M	Danmar Capital · CincyTech · QCA Ventures	—
SERIES BOther financing	Mar 2018	$11M	$44M	CincyTech · Danmar Capital · QCA Ventures	—

Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Growth signals

Airway Therapeutics website traffic

Latest recorded traffic for Airway Therapeutics is 1K monthly website visits, up 44.9% over the last three months. Airway Therapeutics's team grew 6.7% over the past year.

Latest monthly visits1K 3-month web change+44.9% 1-year team growth+6.7%

Monthly website visitsOct 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
HTHalda TherapeuticsPrecision oncology therapies targeting cancer via RIPTAC™ chimera	New Haven, United States	Acquired	40	$126M	$3B
7676bioDegradation by design 76Bio aims to develop transformational therapies for patients with life-threatening disease by pioneering the next generation of	New York City, United States	Operational
SESepternaBiotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors (GPCRs)	San Francisco, United States	Operational
DTDICE TherapeuticsDeveloping transformative medicines for autoimmune and inflammatory diseases	South San Francisco, United States	Acquired
NPNeuromagen PharmDevelops drugs for neurodegenerative diseases including ALS	Beersheba, Israel	Operational
STStratus TherapeuticsDeveloping off-the-shelf hematopoietic stem cell (HSC) therapies to treat a broad range of severe and life-threatening diseases	Natick, United States	Operational
OTOrna TherapeuticsOrna Therapeutics - Ahead of the Curve	Cambridge, United States	Acquired
PTPROSION TherapeuticsPROSION Therapeutics is a drug development company with a proprietary platform that addresses highly unmet medical needs by unlocking undruggables	Cologne, Germany	Operational